Online inquiry

IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8025MR)

This product GTTS-WQ8025MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8025MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14776MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ3641MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ11470MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ12187MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ15202MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ3955MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ9183MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ3976MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BG9924
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW